OBJECTIVE: To investigate the expression and potential clinical usefulness of structure-specific flap endonuclease 1 (FEN-1) in human primary prostate cancer using tissue microarray technology, as FEN-1 was recently identified to be overexpressed in CL1.1, the most aggressive clone generated from the hormone-refractory prostate cancer cell line CL1. MATERIALS AND METHODS: Immunohistochemistry was performed on tissue microarrays constructed from paraffin-embedded specimens of primary prostate cancer from 246 patients who had had a radical prostatectomy. Prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH) and normal prostate epithelium were represented on the array. FEN-1 nuclear expression was scored based on the percentage of target cells staining positively, and correlated with Gleason score, preoperative prostate-specific antigen (PSA) level and pathological stage. The time to PSA recurrence was also analysed. RESULTS: The mean expression of FEN-1 was significantly higher in cancer (36.7%) than in normal (13.2%), BPH (4.5%) and PIN (15.4%) specimens (P < 0.001). FEN-1 expression was significantly correlated with Gleason score (ó = 0.23, P = 0.002). A higher preoperative serum PSA level (P = 0.015), Gleason score > or = 7 (P < 0.001), seminal vesicle invasion (P < 0.001) and capsular involvement (P = 0.004) were associated with PSA recurrence, whereas FEN-1 expression was not. In a multivariate analysis, only Gleason score > or = 7 (P < 0.001), seminal vesicle invasion (P = 0.005) and capsular involvement (P = 0.009) were retained as independent predictors for PSA recurrence. CONCLUSIONS: FEN-1 is overexpressed in prostate cancer compared with matched normal prostate, and its expression increases with tumour dedifferentiation, as shown by increasing Gleason score. These results suggest that FEN-1 might be a potential marker for selecting patients at high risk, and a potential target for prostate cancer diagnosis and therapy.
OBJECTIVE: To investigate the expression and potential clinical usefulness of structure-specific flap endonuclease 1 (FEN-1) in humanprimary prostate cancer using tissue microarray technology, as FEN-1 was recently identified to be overexpressed in CL1.1, the most aggressive clone generated from the hormone-refractory prostate cancer cell line CL1. MATERIALS AND METHODS: Immunohistochemistry was performed on tissue microarrays constructed from paraffin-embedded specimens of primary prostate cancer from 246 patients who had had a radical prostatectomy. Prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH) and normal prostate epithelium were represented on the array. FEN-1 nuclear expression was scored based on the percentage of target cells staining positively, and correlated with Gleason score, preoperative prostate-specific antigen (PSA) level and pathological stage. The time to PSA recurrence was also analysed. RESULTS: The mean expression of FEN-1 was significantly higher in cancer (36.7%) than in normal (13.2%), BPH (4.5%) and PIN (15.4%) specimens (P < 0.001). FEN-1 expression was significantly correlated with Gleason score (ó = 0.23, P = 0.002). A higher preoperative serum PSA level (P = 0.015), Gleason score > or = 7 (P < 0.001), seminal vesicle invasion (P < 0.001) and capsular involvement (P = 0.004) were associated with PSA recurrence, whereas FEN-1 expression was not. In a multivariate analysis, only Gleason score > or = 7 (P < 0.001), seminal vesicle invasion (P = 0.005) and capsular involvement (P = 0.009) were retained as independent predictors for PSA recurrence. CONCLUSIONS:FEN-1 is overexpressed in prostate cancer compared with matched normal prostate, and its expression increases with tumour dedifferentiation, as shown by increasing Gleason score. These results suggest that FEN-1 might be a potential marker for selecting patients at high risk, and a potential target for prostate cancer diagnosis and therapy.
Authors: Keqiang Zhang; Sawa Keymeulen; Rebecca Nelson; Tommy R Tong; Yate-Ching Yuan; Xinwei Yun; Zheng Liu; Joshua Lopez; Dan J Raz; Jae Y Kim Journal: Am J Pathol Date: 2017-10-14 Impact factor: 4.307
Authors: Kathryn A Gold; Edward S Kim; Diane D Liu; Ping Yuan; Carmen Behrens; Luisa M Solis; Humam Kadara; David C Rice; Ignacio I Wistuba; Stephen G Swisher; Wayne L Hofstetter; J Jack Lee; Waun K Hong Journal: Clin Cancer Res Date: 2013-12-23 Impact factor: 12.531
Authors: Tarek M A Abdel-Fatah; Roslin Russell; Nada Albarakati; David J Maloney; Dorjbal Dorjsuren; Oscar M Rueda; Paul Moseley; Vivek Mohan; Hongmao Sun; Rachel Abbotts; Abhik Mukherjee; Devika Agarwal; Jennifer L Illuzzi; Ajit Jadhav; Anton Simeonov; Graham Ball; Stephen Chan; Carlos Caldas; Ian O Ellis; David M Wilson; Srinivasan Madhusudan Journal: Mol Oncol Date: 2014-05-13 Impact factor: 6.603
Authors: Seda Ballikaya; Jennifer Lee; Uwe Warnken; Martina Schnölzer; Johannes Gebert; Jürgen Kopitz Journal: Mol Cell Proteomics Date: 2014-09-15 Impact factor: 5.911
Authors: Dorjbal Dorjsuren; Daemyung Kim; David J Maloney; David M Wilson; Anton Simeonov Journal: Nucleic Acids Res Date: 2010-11-09 Impact factor: 16.971
Authors: Abdulbaqi Al-Kawaz; Islam M Miligy; Michael S Toss; Omar J Mohammed; Andrew R Green; Srinivasan Madhusudan; Emad A Rakha Journal: Breast Cancer Res Treat Date: 2021-06-12 Impact factor: 4.872